Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2012 Mar 1;12(4):289-97. doi: 10.1038/nrc3223.

Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Author information

  • 1Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco CA 94143-0511, USA.

Abstract

Although cancer cells can be immunogenic, tumour progression is associated with the evasion of immunosurveillance, the promotion of tumour tolerance and even the production of pro-tumorigenic factors by immune cells. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) represents a crucial immune checkpoint, the blockade of which can potentiate anti-tumour immunity. CTLA4-blocking antibodies are now an established therapeutic approach for malignant melanoma, and clinical trials with CTLA4-specific antibodies in prostate cancer have also shown clinical activity. This treatment may provide insights into the targets that the immune system recognizes to drive tumour regression, and could potentially improve both outcome and toxicity for patients with prostate cancer.

PMID:
22378189
[PubMed - indexed for MEDLINE]
PMCID:
PMC3433280
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk